Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPVB for Postoperative Pain Management After VATS
NCT06689358Completed
- Sponsor
- King Hussein Cancer Center
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of bupivacaine in postoperative pain (2 arms), sponsored by King Hussein Cancer Center. Primary endpoint: Opioid requirement in the PACU at 4 hours. Started Nov 2022; status: completed.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06689358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06689358.